Curt LaBelle


Dr. LaBelle brings ten years of healthcare growth and venture capital experience to Tullis Health Investors. He has experience as a board member or observer with numerous companies, including Aldagen, Coherex, Impulse Monitoring, KAI Pharmaceuticals, Myocor, and Sirion Therapeutics (sold to Alcon and Bausch & Lomb). He was actively involved in THI's previous investments in Adams (sold to Reckitt Benckiser in 2008 for $2.3 billion) and Adiana (sold to Cytyc in 2007). In addition to his years with THI, Dr. LaBelle has worked as a Vice President at Investor Growth Capital, Inc., a global private equity firm with over $1 billion under management, and with Pfizer in outcomes research and marketing.

Dr. LaBelle holds MD and MBA degrees from Columbia University and completed his internal medicine internship at Columbia's St. Luke's-Roosevelt Hospital.